Exploring Muscle Breakdown During Exercise Recovery

NCT04841772 | Completed

• 1 other identifier: 210203-B-01
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

This study will allow researchers to explore how muscle responds to heavy exercise. The researchers will characterise rates of muscle protein breakdown and synthesis 24hours after heavy exercise with a post exercise protein polyphenol or placebo supplementation. This will inform strategies to help people recover from heavy exercise.

Conditions

Muscle Damage; Healthy

Keywords

Skeletal muscle; Postabsorptive; Muscle protein breakdown; Muscle protein synthesis

Outcome Measures

Primary Outcomes (1)

• Muscle protein breakdown rate

  Muscle protein breakdown rate (FBR, measured in %/h) 24hours post eccentric exercise.

  1hour

Secondary Outcomes (1)

• Muscle protein synthesis rate

  3hours

Study Arms (2)

Vegan Protein

ACTIVE COMPARATOR

Dietary Supplement: Recover Vegan Protein Supplement

Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Interventions

Recover Vegan Protein Supplement DIETARY_SUPPLEMENT

Post exercise protein supplement (26g pea protein)

Vegan Protein

Placebo DIETARY_SUPPLEMENT

Post exercise placebo supplement (32g maltodextrin)

Placebo

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Recreationally active
• years of age

You may not qualify if:

• Regular and structured involvement in resistance training
• Inactive participants
• Habitual dietary protein intake \<0.8g/kg bw/day and \>2.0g/kg bw/day
• Regular use of nutritional supplements known to suppress inflammation or modulate protein metabolism Any diagnosed metabolic conditions (diabetes), cardiovascular disease or hypertension
• Current musculoskeletal injury
• Chronic use of anti-inflammatory medicines
• Any known disorders in muscle metabolism
• Individuals with an allergy to egg, fish, wheat or soy ingredients as the product is manufactured in a facility that contains these ingredients
• Allergy to lidocaine
• Having received or ingested a stable isotope tracer containing 15N in the past
• A personal or family history of epilepsy, seizures or schizophrenia
• Stomach bleeding or stomach ulcer
• Kidney failure
• Liver problems, such as fibrosis, cirrhosis or failure
• Crohns disease or ulcerative colitis

Sponsors & Collaborators

• University of Exeter: lead
• Beachbody: collaborator

Study Sites (1)

University of Exeter

Exeter, Devon, EX1 2LU, United Kingdom

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 9, 2021
• First Posted: April 12, 2021
• Study Start: April 8, 2021
• Primary Completion: December 1, 2022
• Study Completion: December 1, 2022
• Last Updated: March 23, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)